Skip to content

Comparison of Fluoxetine vs Venlafaxine with regards to Efficacy, Safety, and Quality of Life in patients with Major Depressive Disorder

Comparative assessment of Fluoxetine and Venlafaxine for evaluating Efficacy, Safety, and Quality of Life in patients with Major Depressive Disorder: A prospective, observational study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089535
Enrollment
56
Registered
2025-06-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F329- Major depressive disorder, singleepisode, unspecified

Interventions

Control Intervention1: Nil: Nil

Sponsors

Dr Avinash V Turankar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients above 18 years of age, of either gender. 2) Patients with clinically diagnosed major depressive disorder by psychiatrist as per the DSM 5 TR criteria and a HAM-D scale score more or equal to 19. 3) Known MDD patients who have not taken any medication for last 1 month. 4) Patients willing to give written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with history of addiction. 2) Patients with any other long-term treatment like anti-hypertensive, anti-diabetic, anti-tubercular drugs. 3) Patients with neurological disorders (dementia, stroke, seizures), obesity with functional impairment, serious or not stabilized organic brain disorder. 4) Pregnant and lactating women. 5) Known patients of MDD on regular treatment.

Design outcomes

Primary

MeasureTime frame
1)Difference in mean change in the Hamilton Depression Rating Scale (HAM-D) from baseline to the end of the 12-weeks. 2)Difference in mean change in the Beck s Depression Inventory (BDI) scores from baseline to the end of the 12-weeks. Timepoint: Baseline, 4 weeks, 8 weeks, 12 weeks.

Secondary

MeasureTime frame
1) Safety evaluation done by recording and evaluating the adverse events reported by patients. 2) Quality of life evaluation using WHOQOL BREF self-report questionnaire Timepoint: Baseline, 4 weeks, 8 weeks, 12 weeks.

Countries

India

Contacts

Public ContactDr Avinash V Turankar

Government Medical College, Nagpur

aturankar@hotmail.com9822472329

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026